Charles Schwab’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $528M | Buy |
846,306
+41,798
| +5% | +$28.5M | 0.07% | 224 |
|
|
2026
Q1 | $622M | Buy |
804,508
+26,507
| +3% | +$20.3M | 0.1% | 174 |
|
|
2025
Q4 | $601M | Buy |
778,001
+22,436
| +3% | +$15.2M | 0.09% | 181 |
|
|
2025
Q3 | $425M | Buy |
755,565
+35,292
| +5% | +$20M | 0.07% | 238 |
|
|
2025
Q2 | $378M | Buy |
720,273
+13,833
| +2% | +$7.72M | 0.07% | 248 |
|
|
2025
Q1 | $448M | Buy |
706,440
+10,641
| +2% | +$7.32M | 0.08% | 197 |
|
|
2024
Q4 | $496M | Buy |
695,799
+22,538
| +3% | +$18.9M | 0.09% | 181 |
|
|
2024
Q3 | $708M | Buy |
673,261
+11,499
| +2% | +$12.8M | 0.14% | 130 |
|
|
2024
Q2 | $696M | Buy |
661,762
+23,539
| +4% | +$22.8M | 0.13% | 135 |
|
|
2024
Q1 | $614M | Buy |
638,223
+17,607
| +3% | +$16.7M | 0.14% | 122 |
|
|
2023
Q4 | $545M | Buy |
620,616
+22,558
| +4% | +$18.6M | 0.14% | 123 |
|
|
2023
Q3 | $492M | Sell |
598,058
-1,978
| -0.3% | -$1.55M | 0.14% | 120 |
|
|
2023
Q2 | $431M | Buy |
600,036
+4,432
| +0.7% | +$3.42M | 0.12% | 137 |
|
|
2023
Q1 | $489M | Buy |
595,604
+8,661
| +1% | +$6.53M | 0.15% | 122 |
|
|
2022
Q4 | $423M | Buy |
586,943
+13,940
| +2% | +$10.3M | 0.14% | 138 |
|
|
2022
Q3 | $395M | Buy |
573,003
+2,541
| +0.4% | +$1.6M | 0.14% | 126 |
|
|
2022
Q2 | $337M | Buy |
570,462
+8,326
| +1% | +$5.41M | 0.12% | 159 |
|
|
2022
Q1 | $393M | Buy |
562,136
+5,842
| +1% | +$3.7M | 0.12% | 151 |
|
|
2021
Q4 | $351M | Buy |
556,294
+26,766
| +5% | +$16.5M | 0.1% | 170 |
|
|
2021
Q3 | $320M | Buy |
529,528
+24,645
| +5% | +$15.3M | 0.1% | 170 |
|
|
2021
Q2 | $282M | Buy |
504,883
+5,093
| +1% | +$2.58M | 0.09% | 189 |
|
|
2021
Q1 | $236M | Sell |
499,790
-16,359
| -3% | -$7.96M | 0.09% | 203 |
|
|
2020
Q4 | $249M | Buy |
516,149
+5,985
| +1% | +$3.23M | 0.1% | 189 |
|
|
2020
Q3 | $286M | Buy |
510,164
+38,641
| +8% | +$23.4M | 0.13% | 141 |
|
|
2020
Q2 | $294M | Buy |
471,523
+114,426
| +32% | +$65M | 0.14% | 136 |
|
|
2020
Q1 | $174M | Buy |
357,097
+181
| +0.1% | +$74.7K | 0.1% | 193 |
|
|
2019
Q4 | $134M | Sell |
356,916
-12,784
| -3% | -$4.3M | 0.07% | 254 |
|
|
2019
Q3 | $103M | Sell |
369,700
-24,168
| -6% | -$7.15M | 0.06% | 293 |
|
|
2019
Q2 | $123M | Buy |
393,868
+24,540
| +7% | +$8.17M | 0.08% | 257 |
|
|
2019
Q1 | $152M | Buy |
369,328
+72,588
| +24% | +$29.9M | 0.1% | 191 |
|
|
2018
Q4 | $111M | Buy |
296,740
+9,766
| +3% | +$3.57M | 0.08% | 212 |
|
|
2018
Q3 | $116M | Buy |
286,974
+515
| +0.2% | +$196K | 0.08% | 230 |
|
|
2018
Q2 | $98.8M | Sell |
286,459
-10,618
| -4% | -$3.32M | 0.07% | 251 |
|
|
2018
Q1 | $102M | Buy |
297,077
+12,510
| +4% | +$4.35M | 0.08% | 244 |
|
|
2017
Q4 | $107M | Buy |
284,567
+15,924
| +6% | +$6.45M | 0.08% | 223 |
|
|
2017
Q3 | $120M | Buy |
268,643
+23,533
| +10% | +$11.2M | 0.1% | 180 |
|
|
2017
Q2 | $120M | Buy |
245,110
+14,961
| +7% | +$6.55M | 0.11% | 171 |
|
|
2017
Q1 | $89.2M | Buy |
230,149
+12,445
| +6% | +$4.61M | 0.09% | 215 |
|
|
2016
Q4 | $79.9M | Buy |
217,704
+9,113
| +4% | +$3.47M | 0.09% | 224 |
|
|
2016
Q3 | $83.9M | Sell |
208,591
-619
| -0.3% | -$248K | 0.1% | 201 |
|
|
2016
Q2 | $73.1M | Buy |
209,210
+3,741
| +2% | +$1.44M | 0.09% | 225 |
|
|
2016
Q1 | $74.1M | Sell |
205,469
-12,747
| -6% | -$5.25M | 0.1% | 198 |
|
|
2015
Q4 | $118M | Buy |
218,216
+31,441
| +17% | +$17M | 0.16% | 120 |
|
|
2015
Q3 | $86.9M | Buy |
186,775
+9,163
| +5% | +$4.92M | 0.13% | 150 |
|
|
2015
Q2 | $90.6M | Buy |
177,612
+7,922
| +5% | +$3.87M | 0.13% | 159 |
|
|
2015
Q1 | $76.6M | Buy |
169,690
+6,381
| +4% | +$2.7M | 0.11% | 184 |
|
|
2014
Q4 | $67M | Buy |
163,309
+5,736
| +4% | +$2.26M | 0.1% | 199 |
|
|
2014
Q3 | $56.8M | Sell |
157,573
-6,769
| -4% | -$2.27M | 0.09% | 210 |
|
|
2014
Q2 | $46.4M | Buy |
164,342
+8,816
| +6% | +$2.61M | 0.08% | 246 |
|
|
2014
Q1 | $46.7M | Buy |
155,526
+3,842
| +3% | +$1.18M | 0.08% | 232 |
|
|
2013
Q4 | $41.8M | Buy |
151,684
+3,877
| +3% | +$1.12M | 0.08% | 237 |
|
|
2013
Q3 | $46.8M | Buy |
147,807
+8,741
| +6% | +$2.3M | 0.1% | 211 |
|
|
2013
Q2 | $32M | Buy |
+139,066
| New | +$32.4M | 0.07% | 266 |
|
Other funds holding REGN
Charles Schwab's REGN Position: Q2 2026 in Review
Charles Schwab increased its Regeneron Pharmaceuticals (REGN) stake by 5.2% in Q2 2026, buying an estimated $28.5M and bringing the position to 846,306 shares worth $528M. The position accounts for 0.07% of the portfolio, ranked #224.
Charles Schwab first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $708M in Q3 2024. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Charles Schwab held 846,306 shares of Regeneron Pharmaceuticals worth $528M as of Q2 2026.
- Charles Schwab bought 41,798 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $28.5M.
- Regeneron Pharmaceuticals made up 0.07% of Charles Schwab's portfolio in Q2 2026, its #224 holding.
- Charles Schwab first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Regeneron Pharmaceuticals position peaked at $708M in Q3 2024.
- 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.